Repligen Settles With ImClone On Erbitux Suit
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.
ImClone owes no back or future royalties, but will pay $65 million to the Massachusetts biotech and MIT.